Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 1
2008 4
2009 6
2010 4
2011 4
2012 6
2013 10
2014 6
2015 14
2016 20
2017 24
2018 37
2019 39
2020 14
2021 16
2022 17
2023 26
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Association Between Inflammatory Bowel Disease and Viral Infections.
Dehghani T, Gholizadeh O, Daneshvar M, Nemati MM, Akbarzadeh S, Amini P, Afkhami H, Kohansal M, Javanmard Z, Poortahmasebi V. Dehghani T, et al. Among authors: amini p. Curr Microbiol. 2023 Apr 27;80(6):195. doi: 10.1007/s00284-023-03305-0. Curr Microbiol. 2023. PMID: 37106245 Free PMC article. Review.
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, Häner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, Räber L, Heg D, Mach F. Koskinas KC, et al. Among authors: amini p. J Am Coll Cardiol. 2019 Nov 19;74(20):2452-2462. doi: 10.1016/j.jacc.2019.08.010. Epub 2019 Aug 31. J Am Coll Cardiol. 2019. PMID: 31479722 Free article. Clinical Trial.
Radiation-induced inflammation and autoimmune diseases.
Yahyapour R, Amini P, Rezapour S, Cheki M, Rezaeyan A, Farhood B, Shabeeb D, Musa AE, Fallah H, Najafi M. Yahyapour R, et al. Among authors: amini p. Mil Med Res. 2018 Mar 20;5(1):9. doi: 10.1186/s40779-018-0156-7. Mil Med Res. 2018. PMID: 29554942 Free PMC article. Review.
To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps.
Boeltz S, Amini P, Anders HJ, Andrade F, Bilyy R, Chatfield S, Cichon I, Clancy DM, Desai J, Dumych T, Dwivedi N, Gordon RA, Hahn J, Hidalgo A, Hoffmann MH, Kaplan MJ, Knight JS, Kolaczkowska E, Kubes P, Leppkes M, Manfredi AA, Martin SJ, Maueröder C, Maugeri N, Mitroulis I, Munoz LE, Nakazawa D, Neeli I, Nizet V, Pieterse E, Radic MZ, Reinwald C, Ritis K, Rovere-Querini P, Santocki M, Schauer C, Schett G, Shlomchik MJ, Simon HU, Skendros P, Stojkov D, Vandenabeele P, Berghe TV, van der Vlag J, Vitkov L, von Köckritz-Blickwede M, Yousefi S, Zarbock A, Herrmann M. Boeltz S, et al. Among authors: amini p. Cell Death Differ. 2019 Mar;26(3):395-408. doi: 10.1038/s41418-018-0261-x. Epub 2019 Jan 8. Cell Death Differ. 2019. PMID: 30622307 Free PMC article. Review.
Stem Cell Tracing Through MR Molecular Imaging.
Yahyapour R, Farhood B, Graily G, Rezaeyan A, Rezapoor S, Abdollahi H, Cheki M, Amini P, Fallah H, Najafi M, Motevaseli E. Yahyapour R, et al. Among authors: amini p. Tissue Eng Regen Med. 2018 Jan 16;15(3):249-261. doi: 10.1007/s13770-017-0112-8. eCollection 2018 Jun. Tissue Eng Regen Med. 2018. PMID: 30603551 Free PMC article. Review.
Targets for protection and mitigation of radiation injury.
Khodamoradi E, Hoseini-Ghahfarokhi M, Amini P, Motevaseli E, Shabeeb D, Musa AE, Najafi M, Farhood B. Khodamoradi E, et al. Among authors: amini p. Cell Mol Life Sci. 2020 Aug;77(16):3129-3159. doi: 10.1007/s00018-020-03479-x. Epub 2020 Feb 18. Cell Mol Life Sci. 2020. PMID: 32072238 Review.
230 results